1 The mystery of COVID-19 reinfections: A global systematic

² review and meta-analysis of 577 cases

- 3 Rubaid Azhar Dhillon¹, Mohammad Aadil Qamar², Omar Irfan^{3*}, Jaleed Ahmed Gilani⁴, Usama
- 4 Waqar⁵, Mir Ibrahim Sajid⁵, Syed Faisal Mahmood⁶
- ⁵ ¹Medical College, Riphah International University, Rawalpindi, Pakistan.
- ⁶ ²Ziauddin Medical College, Karachi, Pakistan.
- ³Centre for Global Child Health, Hospital for Sick Children, Toronto, Canada.
- ⁴Aga Khan University Hospital, Karachi, Pakistan.
- ⁵Medical College, Aga Khan University, Karachi, Pakistan.
- ⁶Section of Infectious Diseases, Aga Khan University, Karachi, Pakistan.
- ¹¹ [¶]These authors contributed equally to this work. RAD and MAQ are Joint first authors.

12

13 Abstract

14 Background

- 15 As the COVID-19 pandemic rages on, reports on disparities in vaccine roll out alongside
- 16 reinfection and reactivation from previously recovered cases have been emerging. With newer
- 17 waves and variants of COVID-19, we conducted a systematic review to assess the determinants
- 18 and disease spectrum of COVID-19 reinfection.

19 Methods

20	A comprehensive search covering relevant databases was conducted for observational studies
21	reporting Polymerase Chain Reaction (PCR) confirmed infection and reinfection cases. Quality
22	assessment tool developed by the National Institute of Health (NIH) for assessment of case
23	series was used. Meta-analyses were performed using RevMan 5.3 for pooled proportions of
24	findings in first infection and reinfection with 95% confidence interval (CI).

25 **Results**

Eighty-one studies reporting 577 cases were included from 22 countries. The mean age of 26 patients was 46.2±18.9 years with males accounting for 45.8% of the study population while 27 28 179 (31.0%) cases of comorbidities were reported. The average time duration between first infection and reinfection was 63.6±48.9 days. During first infection and reinfection, fever was 29 the most common symptom (41.4% and 36.4%, respectively) whilst anti-viral therapy was the 30 most common treatment regimen administered (44.5% and 43.0%, respectively). Overall, 31 comparable odds of symptomatic presentation and management were reported in the two 32 33 infections. However, a higher Intensive Care Unit (ICU) admission rate was observed in 34 reinfection compared to first infection (10 vs 3). Ten deaths were reported with 565 patients fully recovering. Respiratory failure was the most common cause of death (7/10 deaths). 35 Seventy-two studies were determined to be of good quality whilst nine studies were of fair 36 37 quality.

38 Conclusion

39	As the first global-scale systematic review of its kind, our findings support immunization
40	practices given increased ICU admissions and mortality in reinfections. Our cohort serves as a
41	guide for clinicians and authorities for devising an optimal strategy for controlling the
42	pandemic.
43	Keywords: COVID-19, Reinfection, LMIC, HIC, Reactivation
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	

54 Introduction

55	The coronavirus, through its rapid spread and emerging variants, started in Wuhan amid
56	December 2019. It was declared a global pandemic in March 2020 and persists as a public
57	healthcare emergency. Over this period of more than a year, till date, the virus has infected
58	more than 165 million individuals globally, and has resulted in more than 3.4 million deaths [1].
59	Currently, there are seven types of corona viruses known to infect humans: 4 are seasonal and
60	cause limited upper respiratory tract infections, but 3 of them, namely SARS coronavirus (SARS-
61	CoV-1), Middle East respiratory syndrome (MERS), and SARS-CoV-2 cause severe disease [2].
62	SARS COV-2, the cause of the current pandemic, causes infection by binding to the angiotensin
63	converting enzyme 2 receptor using a receptor binding domain in its spike protein for cell entry
64	and ultimately, resulting in a respiratory syndrome [2-4]. The currently available vaccines target
65	the spike protein[2]. However, mutations in the spike protein have been implicated in the
66	reduction of small, but significant, efficacy of vaccines [5, 6] highlighting the scale of the
67	challenge COVID-19 places to the world.
68	Even though the world is heralding the development of new vaccines as a potential way
69	forward for a healthy, more "COVID-free" time, the concern of reinfection, recurrence, and

70 mutant variants looms. The Center for Disease Control and Prevention (CDC), in their 27th

71 October 2020 update[7] raised concerns over reactivation of the disease and requested the

72 public to maintain infection control measures, such as wearing a mask in public, maintaining a

six feet distance, regular hand washing, and avoiding crowded spaces.

74	Since Tillett et al.,[8] described the first confirmed case of COVID-19 reinfection from the USA,
75	many authors have described their patient experiences of viral recurrence. The reason for this
76	recurrence and its potential public health implication is a question that warrants explanation.
77	Iwasaki et al.,[9] reason that perhaps a scant antibody response following the first infection
78	could be the cause of a relapse. They emphasize on ascertaining a degree of specificity of the
79	antibody (anti-nucleocapsid vs anti-spike antibody) at the time of reinfection, as well as
80	determine the immune correlations of protection.
81	The public concern of whether vaccines could be a potential cure for the viral outbreak remains
82	to be explained, with the obvious apprehension of whether a separate vaccine would be
83	required for every variant of the virus. Till date, they have been four variants with significant
84	mutations in the spike protein that have gained wide spread surveillance: B.1.1.7 (VOC
85	202012/01 or 20B/501Y.V1) which originated in the UK, B.1.351 (20H/501Y.V2) which
86	originated from the Republic of South Africa, and P.1 (B.1.1.28.1) which was reported in
87	travelers coming from Brazil [10]. A fourth double mutant variant of concern, labeled B.1.617
88	coming out from India, has been reported in March 2021 and is being investigated, considered
89	to be a cause of the massive rise in infections in India currently experiencing its second wave
90	[11].

A few questions remain though. Firstly, would immunity conferred by the first infection protect
individuals from a serious disease process in the reinfection phase? And secondly, does
reinfection imply that individuals who are already vaccinated experience a more severe COVID19 infection? The objective of this review, in addition to providing a comprehensive evidence

- 95 on COVID-19 reinfections including both pediatric and adult cases, is a unique comparison of
- 96 first infection and the reinfection disease spectrum, management, and outcomes.

97 Methods

- 98 The protocol of the review is registered with PROSPERO CRD42021239816. The review is
- 99 reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-
- 100 Analyses (PRISMA).

101 Search methods

- 102 An exhaustive literature review was conducted on major databases: PubMed, WHO COVID-19
- 103 Database, Embase, China National Knowledge Infrastructure (CNKI) Database, Google Scholar,
- 104 manual searches of leading medical journals, and a pre-print server, medRxiv, covering the
- 105 timeline of January 1st, 2020, to March 16th, 2021. The following keywords were used to
- 106 conduct the search: COVID-19 and derivatives, reinfection, relapse, reactivation, as shown in S1
- 107 Table. Complementary searches were conducted in the John Hopkins Health Resource, Chinese
- and US CDC Library. No language restrictions were applied. Key reference lists were additionally
- 109 screened for more studies.

Selection strategy

Observational studies (cohorts, case series, and case reports) reporting laboratory-confirmed
 COVID-19 (RT-PCR) first infection and reinfection were considered for inclusion. Review articles,
 commentaries, and letters not presenting any original data were excluded. Covidence software

114	(2016 edition) was used for screening by two reviewers independently and in duplicate. Any
115	discrepancies in selection were resolved by a third independent author.

Data extraction and analysis 116

117

118 data form by two reviewers. The information extracted was as follows: Author names, date of 119 publication, country, setting of study, type of study, number of patients and age group, patient information (age, gender and comorbidities), clinical evaluation (presenting symptoms in both 120 121 infections, travel/exposure history and infected family members), diagnostic tests (nasopharyngeal swabs, antibody tests and timelines for initial infection and reinfection). 122

The shortlisted articles were then extracted independently and in duplicate, on a structured

radiographic findings, therapeutic regimen (medications, isolation, and plasma therapy), 123

124 outcomes for both infections (hospitalization, ICU admission, complications, discharge, and

125 death) and antibody status after both infections. Disaggregated data by age groups (children

and adults) was extracted where available. 126

127 Categorical data was summarized as counts and proportions. The pooled proportions of reported findings were calculated using Review Manager 5.3's random-effects model. I² was 128

calculated to examine statistical heterogeneity. The clinical features and outcomes were 129

130 compared accordingly between first infection and reinfection using pooled proportions and

131 their 95% CIs, supplemented by an odds ratio (OR).

Quality assessment 132

Quality assessment of included studies was conducted using the tool developed by the National 133 134 Institute of Health (NIH) for assessment of case series. Two authors independently scored the

135	quality of case series out of 8, based on the clarity of study objectives, case definition,
136	consecutive subject recruitment, comparability of subjects, definition and measurement of
137	outcomes, length of follow-up, statistical methods, and results. A case series scoring 6-8 was
138	considered good quality, 4-5 was considered fair quality and <4 was considered poor quality.
139	Consecutive subject recruitment, comparability of subjects and statistical methods were
140	excluded from the scoring criteria for case reports, which were scored out of 5. Case reports
141	scoring 5 were considered good quality, scoring 3-4 were considered fair quality, and scoring <3
142	were considered poor quality.

143 **Results**

- 144 The comprehensive literature search yielded a total of 980 studies after removal of duplicates.
- 145 After title and abstract screening, 87 studies were found to be eligible for a full-text
- assessment, of which, 81 were found to be eligible according to our inclusion criteria[8, 12-91].
- 147 The characteristics of the 81 included studies is shown in S2 Table. Six studies were excluded as
- 148 they presented overlapping or missing data. An overview of the detailed systematic study
- selection process is presented in the PRISMA flow diagram (Fig 1).

150 Fig 1. PRISMA Flow diagram of study selection process.

- 151 Through consultation with a professional librarian, a search was conducted in leading medical
- 152 journals and through duplication and screening processes, studies were selected.
- 153 In terms of study types, 45 studies (55.6%) were case reports, and 36 studies (44.4%) were case
- 154 series. Studies were reported from 22 countries. Forty-eight out of 81 studies were reported
- 155 from low-and-middle-income countries (LMICs). More than one-third of the studies were

- reported from China (28/81, 34.6%), almost one-sixth were from the USA (11/81, 13.6%),
- accounting together for about half of the studies (39/81, 48.1%) included in our review. The
- 158 global distribution of studies is shown in Table 1 and S1 Fig.

159 Table 1. Distribution of studies (N=81) and reinfection cases (N=577) according to country of

160 **origin included in the review.**

Country	Number of studies	Number of reinfection cases
Belgium	2	2
Brazil	7	45
China	28	423
Colombia	1	1
Ecuador	1	1
France	5	19
Hong Kong	3	3
India	4	8
Iraq	1	26
lsrael	1	1
ltaly	4	4
Iran	1	9
Netherlands	1	1
Pakistan	1	1
Peru	1	1
Portugal	1	1
Qatar	1	1
UK	3	8
USA	11	14
Turkey	2	3
Switzerland	1	1
Korea	1	4
Total	81	577

161

Demographics and Epidemiology

163 A total of 577 cases with a mean age of 46.2±18.9 years (range 3.0 – 91.0 years) were included

in the study. The gender of study cases was noted to be 45.8% males and 53.7% females. Of the

165	577 cases, approximately one-third of the cases (n=179, 31.0%) were reported to have at least
166	one comorbidity. Reports of having a positive contact history with a close contact or a family
167	member with COVID-19 were found in 87 (15.1%) cases (S2 Table and Table 2). Across 76
168	studies, the average reported time duration between first infection and reinfection was 63.6 \pm
169	48.9 days (range 11.0 – 210.0 days).

170 **Table 2. Demographics of Patients.**

Variable	Mean Proportion (%)		
	46.2 ± 18.9 years (range 3.0 – 91.0		
Age (Years)	years)		
Gender			
Male	264 (45.8)		
Female	310 (53.7)		
Not specified	3(0.5)		
Contact History Positive	87 (15.1)		
Underlying Comorbidities	179 (31.0)		
Average time duration between	63.6 ± 48.9 days (range 11.0 – 210.0		
first infection and reinfection	days)		

171

172 Clinical features during first infection and reinfection

Around three-fourth of our cases were categorized as being mildly symptomatic with only 10 cases being classified as severe to critical by their respective studies for disease severity in the first infection. The total number of asymptomatic cases during the first infection was 53 (9.2%) with an increase to 184 (31.9%) cases noted during reinfection (S2 Table). Tian M et al.,[72] reported the highest number of asymptomatic cases (20/577, 3.5%) during the first infection whereas An J et al.,[17] with 27 cases (4.7%) reported the highest number of asymptomatic cases during reinfection. The presence of antibodies was also reported for the total 577 cases,

- 180 wherein 323 (56.0%) and 364 (63.0%) cases were detected to be positive during first infection
- 181 and reinfection, respectively.
- 182 The most common presenting symptoms amongst patients in the first infection were fever
- 183 (n=239, 41.4%) and cough (n=201, 34.8%), which then accounted for 36.4% (n=210) and 34.8%
- 184 (n=201) of cases, respectively, during reinfection. Myalgia was reported in 80 (13.9%) cases
- 185 during first infection which increased to 88 (15.3%) cases during reinfection. The frequencies
- and odds ratio of other reported signs and symptoms are listed in Fig 2.
- 187 Fig 2. Clinical features of First Infection and Reinfection (N=577)
- 188 Regarding the radiological imaging during first infection of the 577 cases, almost one-quarter
- 189 (146/577, 25.3%) had not reported, or did not have, any kind of chest imaging done. Out of
- 190 those who reported, only 25 (4.3%) cases had a normal finding whereas 295 (51.1%) cases
- reported an abnormality with Chen et al., [27] reporting the highest occurrence of radiological
- abnormalities (70 out of 81 cases, 86.4%).

193 Management of first infection and reinfection

- 194 The most administered treatment, as reported by the study results, was antiviral therapy
- accounting for 44.5% (n=257) and 43.0% (n=248) of cases during first infection and reinfection,
- respectively. Administration of antibiotics was lower at 14.4% (n=83) and 13.2% (n=76) for first
- 197 infection and reinfection respectively (Fig 3).
- 198 Fig 3. Management of First Infection and Reinfection (N=577)

199	In the study by He et al. [42], 60% of patients were administered steroids during both
200	infections, which was reported to be the highest use of steroids amongst studies reported to
201	date. However, in our data, the overall use of steroids stood at 16.6% (n=96) and 12.1% (n=70)
202	during the respective infections. Traditional Chinese medicine and interferon administration
203	were reported at 13.9% (n=80) and 10.7% (n=62) during the first infection and 26.7% (n=154)
204	and 7.6% (n=44) during reinfections, respectively.
205	Lastly, our results show that the use of low flow oxygen stood at 6.1% (n=35) of cases during
206	the first infection which then doubled to 12.3% (n=71) of cases during reinfection (Fig 3). Out of
207	the total studies, reports of ICU admission and mechanical ventilation was relatively low being
208	0.5% (n=3) and 0.3% (n=2) during first infection, respectively, compared to 1.7% (n=10) and
209	1.6% (n=9) during reinfection, respectively. This was contradictory to a higher number of
210	asymptomatic cases observed in the reinfection phase, implicating for a possible need of an
211	Individual Patient Data (IPD) analysis in future studies.
212	Comparable odds of symptomatic presentation (OR:0.93, 95%CI: 0.74-1.17) and management
213	(OR:0.90, 95%CI: 0.63-1.29) were observed in the first infection compared to reinfection when
214	meta-analyzed, as shown in Fig 2 and Fig 3. Although a higher event of management was
215	observed in the first infection, due to the individual weight of the studies, the overall OR
216	favored first infection and was less than 1.

217 Outcomes of first infection and reinfection

218 Complete recovery rate after reinfection stood at 97.9% (565 cases) with a total of 10 (1.8%)

deaths. The outcome status was unknown for 2 cases (0.3%) (S2 Table). The eight expired cases

were elderly (72-91 years old; 1 male and 7 females) and 2 cases were middle-aged adults (44

- and 54 years old; both males). Seven cases had comorbidities involving multiple organ systems
- whilst three suffered from hypertension and the remaining one had an underlying malignancy.
- 223 Respiratory failure was the most common cause of death (Seven out of ten deaths).

224 Pediatric (0-19 years) reinfection cases

- Out of 577 cases, disaggregated data for 24 pediatric (0-18 years) cases was available.
- Disaggregation reported positive contact histories in 7 cases (29.2%) with only 1 (4.2%)
- reporting a comorbidity. A total of 7 cases (29.2%) were asymptomatic followed by fever (n= 4,
- 16.7%) and cough (n= 3, 12.5%) in first infection whereas during reinfection, asymptomatic
- 229 presentation (n= 7, 29.2%) was followed by cough (n= 4, 16.7%) and then fever (n= 3, 12.5%).
- 230 With 9 abnormal chest X-ray findings (37.5%), the most frequently used management
- 231 modalities during first infection and reinfection were anti-viral (n=12) and traditional Chinese
- 232 Medicine (n=12), respectively. All patient outcomes were reported as recovered.

233 Quality assessment of included studies

- 234 Seventy-two studies were determined to be of good quality while nine studies were of fair
- quality (S3 Table). Studies were primarily downgraded for unclear study objectives[63],
- incomplete case definition[16, 28, 48, 66, 67, 70, 77, 83], non-consecutive subject
- 237 recruitment[19, 27, 30, 34, 38, 39, 44-46, 49, 71, 79, 80, 86, 90], incomparable subjects[79],
- inadequate length of follow-up[43, 63], inadequate description of statistical methods[39, 46,
- 80] and inadequate description of results[39, 78]. The most common cause for downgrading
- 240 studies was non-consecutive recruitment which raised concerns that the included sample could

be biased towards a more severe presentation or included more individuals undergoing routine
screening.

243 **Discussion**

Both the developing and developed world are still battling the spread of COVID-19. A major

concern that needs to be addressed is the appearance of reinfections in previously recovered

246 COVID-19 patients.

247 Our review is the first, and largest, systematic review covering COVID-19 reinfection cases from

248 over 22 countries, raising questions concerning vaccination and exploring a specific set of

249 determinants that can facilitate reinfection in recovered individuals. Similar systematic reviews

on COVID-19 reinfection have been conducted previously[92, 93] but none of those studies, or

any conducted so far in the literature, have been as extensive as this review in terms of

analyzing the clinical information between first infection and reinfection whilst covering a wide

range of international and regional databases. One of the major strengths of this review is the

substantial timeframe that it covers: January 2020 to March 2021, spanning a total of 81 studies

with a widespread distribution of High-Income Countries (HICs) and LMICs to differentiate

256 features of reinfection cases as per different settings. In addition, adult cases were separated

257 from pediatric cases to differentiate between clinical features and identify the optimal

treatment management strategies as per varying age groups. Furthermore, case reports and

case series included in our study were quality assessed with 72 out of 81 studies reported to be

of good quality. An analysis of only pediatric reinfection cases was also conducted in this

261 review. Good prognosis and lower morbidity were reported in the pediatric cases, similar to the

general COVID-19 disease course in the pediatric population[94]. Therefore, we suggest public
health campaigns targeting people of younger age as they are at similar risk of reinfection as
adults, to ensure elimination of complacency and enforcement of protective measures, such as
face masks and social distancing.

266 A broad distribution was seen amongst severity of first infection compared to reinfection as well as management and number of symptomatic cases. The most reported clinical symptoms 267 268 in our review were fever (41.4%) and cough (34.8%) in first infection with a frequency of 36.4% 269 cases with fever and 34.8% cases with cough in reinfection, respectively. These findings are 270 similar to a trend observed in the review on reinfections by Gidari et al. [95] In addition, the 271 number of asymptomatic cases in our review increased from 9.2% in first infection to 31.9% in second infection, similar to findings reported in the review by Gidari et al[95]. On the contrary, 272 273 a higher requirement of ICU admission and mechanical ventilation was observed during 274 reinfection in our review. A meta-analysis analysis of 123 cases by Vancsa et al [96] showed that the second episode of SARS-COV-2 infection is more severe than the first if it happens within 60 275 276 days of the first positive PCR. This deems the necessity of IPD analysis as many of the larger 277 case series report more severe cases which might skew the overall findings. A total of 10 deaths 278 were reported in this review, all amongst reinfection cases. In all 10 cases, several 279 comorbidities were present and all patients who were classified as the most severe were of 280 older age, a similar trend seen in a study by Wang et al. [97] Most of these patients died due to 281 respiratory complications; similar effects of these comorbidities can be seen in other respiratory illnesses such as MERS-CoV[98]. The results from this review suggest that 282 283 comorbidities and age play a major role in the outcome of critical patients.

The time duration between first infection and reinfection has been a source of debate. Alinaghi 284 et al. in their systematic review[93] estimated that antibodies from natural infection lasted 40 285 days, after which the chances of reinfection increased. The average time duration between first 286 infection and reinfection in our review was 63.6 days. Wang et al. in their review noted it to be 287 288 76 days[99] whereas Manish et al. in their review[100] observed a lengthier duration of median 113.5 days. This variation in time duration outlines the need for vigilance when it comes to 289 COVID-19 reinfection, especially considering waning antibodies. 290 Another observation made in our review was differences in the presence of antibodies during 291 first infection and reinfection. A recently published systematic review looked at antibody 292 293 response following SARS-COV-2 infection across multiple studies [101]. They noted that 80% of patients developed IgM antibodies with antibodies being detected after a mean period of 7 294 295 days and declining after 27 days, and 95% of patients developed IgG antibodies with antibodies 296 being detectable after a mean period of 12 days and started declining after 60 days. Likewise, IgA levels and neutralizing antibodies started declining after 30 days. In our review, 56.0% and 297 63.0% of the patients detected positive for antibodies during first infection and reinfection, 298 299 respectively. Some evidence suggests that waning antibodies places individuals at a risk for 300 reinfection, which may explain our finding of the time duration of first infection and reinfection 301 being a mean of 63 days. The presence of antibodies could provide a protective role, but it does 302 not specifically prevent reinfection as supported by findings in a systematic review by Piri et 303 al.[102]

Whilst our review did not analyze the cause of reinfection being due to different variants, they
 cannot be excluded. A review by Wang et al.[99] concluded that previous COVID-19 reinfection

did not confer total immunity and a second infection by a different variant was possible with
the second infection being more severe than the first. Even though most of the studies in our
review predated the announcements of the new variants, however, given the ability of the virus
to mutate at a rapid pace, some reinfection cases reported in our study could be due to the
variants which would have resulted in more severity of reinfection. Whether waning antibodies
or new variants were the source of reinfection is a question that should be explored further in
future studies.

313 A recent systematic review by Azam et al. looked at the incidence of SARS-COV-2 positivity in 314 patients who had recovered from COVID-19 [103]. They noted that younger patients and those 315 with a longer initial infection were more likely to have recurrent positivity. A similar systematic review by Manish et al. on the assessment of SARS-COV-2 mutations in reinfections and 316 317 persistent infections[100] noted it to be challenging to differentiate between reinfection and 318 persistent recurrent infection, concluding that the former happened in immunocompetent individuals and the latter happened in immunocompromised individuals. Furthermore, this 319 320 phenomenon was associated with a faster viral evolution and mutation resulting in the creation of new variants. Lastly, another systematic review by Hoang on the risk factors associated with 321 re-positive viral RNA after recovery from COVID-19 [104] postulated that the re-positive viral 322 323 RNA seen in their review likely added to the evidence that viral relapse was a cause of COVID-324 19 recurrence.

This review has some limitations, such as the small sample sizes analyzed from each country except for China that had 73% (n=423) of the total included cases. The majority of these cases were reported from Wuhan or the Hubei province, where the gross domestic product per

capita is less than half of that of Beijing and Shanghai [105]. Therefore, the findings of studies 328 329 from China may be generalizable to the socioeconomic and health development status of other middle-income countries and not to high-income nations. This review can be improved by 330 sampling larger series and including IPD, if available, to predict the outcome of COVID-19 illness 331 332 based off epidemiological trends dramatically reducing hospitalization time, given the lack of sufficient healthcare resources in low-middle income countries. Therefore, a selection bias 333 334 remains when considering LMICs where admitted hospital patients could be in a more critical 335 state reporting a higher mortality rate. Our review on reinfections in COVID-19 also comes at a pertinent time as countries, especially 336 the developing world, suffer a repeated wave of infection [106]. At this time, public health 337 initiatives aimed at removing complacency are the need of hour, and one of the key messages 338 339 that needs to be given is that reinfection is a reality and vaccines along with social distancing 340 remain the key in fighting the pandemic. A recently published online longitudinal survey [107] in 23 countries of high, middle and low income, across 4 continents with over 1 million 341 participants provides hope in this regard, as it identified that the intention to vaccinate 342 amongst the general public is at an all-time high, with the major issue not being vaccine 343 hesitancy but a shortage of vaccines. A recent report of a 4 month surveillance of mass 344 345 immunization in Israel [108] notes two doses of the Pfizer BioNTech mRNA COVId-19 vaccine to be highly effective (95.3%; 95% CI 94·9–95·7) against SARS-CoV-2 infection and mitigated 346 347 COVID-19-related hospitalizations, severe disease, and death, including those caused by variants including the B.1.1.7 SARS-CoV-2. Whilst the world is still under process of getting 348 349 vaccinated, data needs to be collected on patients in the long run to analyze whether

350	vaccination has an	y correlation with	reinfection case	ses and further i	investigate the aver	age time
-----	--------------------	--------------------	------------------	-------------------	----------------------	----------

- 351 needed by the various vaccines to achieve their desired efficacies. We hope that governments
- across the world seize this moment and take steps to ensure equitable distribution of vaccines
- so that the world can finally step out of the long shadow cast by the COVID-19 pandemic.

354 **Conclusion**

- 355 COVID-19 first infections and reinfections observe a similar clinical spectrum and management
- regimen with a slightly higher severity reported during reinfection in the form of requirement
- 357 for mechanical ventilation and ICU admission. There lies a need for much closer scrutiny of
- reinfections globally with individual patient data analysis to derive determinants of reinfection
- 359 incidence and disposition to a severe infection.
- 360 Acknowledgements: None.

361 **References**

- 1. COVID-19 Dashboard [Internet]. Johns Hopkins University. 2021 [cited 20th May 2021].
- 363 Available from: <u>https://coronavirus.jhu.edu/map.html</u>.
- 2. Fergie J, Srivastava A. Immunity to SARS-CoV-2: Lessons Learned. Front Immunol.
- 2021;12:654165. Epub 2021/04/06. doi: 10.3389/fimmu.2021.654165. PubMed PMID:
- 366 33815415; PubMed Central PMCID: PMCPMC8018176.
- 367 3. Costa AOC, Neto HdCA, Nunes APL, de Castro RD, de Almeida RN. COVID-19: ls
- reinfection possible? EXCLI Journal. 2021;20:522-36.
- 369 4. Khoshkam Z, Aftabi Y, Stenvinkel P, Paige Lawrence B, Rezaei MH, Ichihara G, et al.
- Recovery scenario and immunity in COVID-19 disease: A new strategy to predict the potential of

- reinfection. J Adv Res. 2021. Epub 2021/02/02. doi: 10.1016/j.jare.2020.12.013. PubMed PMID:
- 372 33520309; PubMed Central PMCID: PMCPMC7832464.
- 373 5. Prevost J, Finzi A. The great escape? SARS-CoV-2 variants evading neutralizing
- responses. Cell Host Microbe. 2021;29(3):322-4. Epub 2021/03/12. doi:
- 10.1016/j.chom.2021.02.010. PubMed PMID: 33705702; PubMed Central PMCID:
- 376 PMCPMC7945862.
- 377 6. Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, et al. mRNA vaccine-
- elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021. Epub 2021/02/11. doi:
- 379 10.1038/s41586-021-03324-6. PubMed PMID: 33567448.
- 380 7. CDC. Reinfection with COVID-19. <u>https://www.cdc.gov/coronavirus/2019-ncov/your-</u>
- 381 <u>health/reinfection.html.2020</u>.
- 382 8. Tillett RL, Sevinsky JR, Hartley PD, Kerwin H, Crawford N, Gorzalski A, et al. Genomic
- evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect Dis. 2021;21(1):52-8. Epub
- 2020/10/16. doi: 10.1016/S1473-3099(20)30764-7. PubMed PMID: 33058797; PubMed Central
- 385 PMCID: PMCPMC7550103.
- 386 9. Iwasaki A. What reinfections mean for COVID-19. The Lancet Infectious Diseases.
- 387 2021;21(1):3-5. doi: 10.1016/s1473-3099(20)30783-0.
- 10. Gomez CE, Perdiguero B, Esteban M. Emerging SARS-CoV-2 Variants and Impact in
- 389 Global Vaccination Programs against SARS-CoV-2/COVID-19. Vaccines (Basel). 2021;9(3). Epub
- 390 2021/04/04. doi: 10.3390/vaccines9030243. PubMed PMID: 33799505; PubMed Central
- 391 PMCID: PMCPMC7999234.

392	11.	Welfare MoHAF. Genome Sequencing by INSACOG shows variants of concern and a			
393	Novel	variant in India. <u>https://pib.gov.in/PressReleaselframePage.aspx?PRID=1707177</u> : PIB			
394	Delhi; 2021.				
395	12.	Abdallah H, Porterfield F, Fajgenbaum D. Symptomatic relapse and long-term sequelae			
396	of COV	ID-19 in a previously healthy 30-year-old man. BMJ Case Rep. 2020;13(12):e239825-e.			
397	Epub 2	020/12/16. doi: 10.1136/bcr-2020-239825. PubMed PMID: 33318288; PubMed Central			
398	PMCID	: PMCPMC7736956.			
399	13.	Adrielle Dos Santos L, Filho PGG, Silva AMF, Santos JVG, Santos DS, Aquino MM, et al.			
400	Recurr	ent COVID-19 including evidence of reinfection and enhanced severity in thirty Brazilian			
401	health	care workers. J Infect. 2021;82(3):399-406. Epub 2021/02/17. doi:			
402	10.101	6/j.jinf.2021.01.020. PubMed PMID: 33589297; PubMed Central PMCID:			
403	PMCPN	ИС7880834.			
404	14.	Ak R, Yilmaz E, Seyhan AU, Doganay F. Recurrence of COVID-19 Documented with RT-			
405	PCR. J	Coll Physicians Surg Pak. 2021;30(1):S26-S8. Epub 2021/03/03. doi:			
406	10.292	71/jcpsp.2021.01.S26. PubMed PMID: 33650420.			
407	15.	Ali AM, Ali KM, Fatah MH, Tawfeeq HM, Rostam HM. SARS-CoV-2 Reinfection in Patients			
408	Negati	ve for Immunoglobulin G Following Recovery from COVID-19. medRxiv; 2020. p.			
409	2020.1	1.20.20234385-2020.11.20.			
410	16.	Alonso FOM, Sabino BD, Guimaraes M, Varella RB. Recurrence of SARS-CoV-2 infection			
411	with a	more severe case after mild COVID-19, reversion of RT-qPCR for positive and late			
412	antibo	dy response: Case report. J Med Virol. 2021;93(2):655-6. Epub 2020/08/17. doi:			
413	10.100	2/jmv.26432. PubMed PMID: 32797634; PubMed Central PMCID: PMCPMC7436374.			
		21			

414	17.	An J, Liao X, Xiao T, Qian S, Yuan J, Ye H, et al. Clinical characteristics of recovered					
415	COVID-19 patients with re-detectable positive RNA test. Ann Transl Med. 2020;8(17):1084.						
416	Epub 2020/11/05. doi: 10.21037/atm-20-5602. PubMed PMID: 33145303; PubMed Central						
417	PMCID: PMCPMC7575971.						
418	18. Arteaga-Livias K, Panduro-Correa V, Pinzas-Acosta K, Perez-Abad L, Pecho-Silva S,						
419	Espinoza-Sanchez F, et al. COVID-19 reinfection? A suspected case in a Peruvian patient. Travel						
420	Med Infect Dis. 2021;39(Jan-Feb 2021):101947. Epub 2020/12/12. doi:						
421	10.102	16/j.tmaid.2020.101947. PubMed PMID: 33307196; PubMed Central PMCID:					
422	PMCP	MC7723440.					
423	19.	Atici S, Ek OF, Yildiz MS, Sikgenc MM, Guzel E, Soysal A. Symptomatic recurrence of					
424	SARS-0	CoV-2 infection in healthcare workers recovered from COVID-19. J Infect Dev Ctries.					
425	2021;2	L5(1):69-72. Epub 2021/02/12. doi: 10.3855/jidc.14305. PubMed PMID: 33571147.					
426	20.	Bellanti F, Lo Buglio A, Custodero G, Barbera L, Minafra G, Montrano M, et al. Fatal					
427	relapse of COVID-19 after recovery? A case report of an older Italian patient. J Infect.						
428	2021;8	32(1):e49-e51. Epub 2020/12/20. doi: 10.1016/j.jinf.2020.12.009. PubMed PMID:					
429	33340595; PubMed Central PMCID: PMCPMC7834308.						
430	21.	Bellesso M, Bruniera FR, Trunkel AT, Nicodemo IP. Second COVID-19 infection in a					
431	patien	t with multiple myeloma in Brazil - reinfection or reactivation? Hematol Transfus Cell					
432	Ther. 2021;43(1):109-11. Epub 2021/01/12. doi: 10.1016/j.htct.2020.12.002. PubMed PMID:						
433	33423984; PubMed Central PMCID: PMCPMC7837121.						

434 22. Bongiovanni M. COVID-19 reinfection in a healthcare worker. J Med Virol.

- 435 2020:jmv.26565-jmv. Epub 2020/09/30. doi: 10.1002/jmv.26565. PubMed PMID: 32990954;
- 436 PubMed Central PMCID: PMCPMC7537129.
- 437 23. Bonifacio LP, Pereira APS, Araujo D, Balbao V, Fonseca B, Passos ADC, et al. Are SARS-
- 438 CoV-2 reinfection and Covid-19 recurrence possible? a case report from Brazil. Rev Soc Bras
- 439 Med Trop. 2020;53:e20200619. Epub 2020/09/24. doi: 10.1590/0037-8682-0619-2020.
- 440 PubMed PMID: 32965458; PubMed Central PMCID: PMCPMC7508196.
- 441 24. Cao H, Ruan L, Liu J, Liao W. The clinical characteristic of eight patients of COVID-19 with
- 442 positive RT-PCR test after discharge. J Med Virol. 2020;92(10):2159-64. Epub 2020/05/16. doi:
- 443 10.1002/jmv.26017. PubMed PMID: 32410245; PubMed Central PMCID: PMCPMC7272974.
- 444 25. Chan PKS, Lui G, Hachim A, Ko RLW, Boon SS, Li T, et al. Serologic Responses in Healthy
- 445 Adult with SARS-CoV-2 Reinfection, Hong Kong, August 2020. Emerg Infect Dis.
- 446 2020;26(12):3076-8. Epub 2020/10/23. doi: 10.3201/eid2612.203833. PubMed PMID:
- 447 33089772; PubMed Central PMCID: PMCPMC7706979.
- 448 26. Chen D, Xu W, Lei Z, Huang Z, Liu J, Gao Z, et al. Recurrence of positive SARS-CoV-2 RNA
- 449 in COVID-19: A case report. Int J Infect Dis. 2020;93(Apr):297-9. Epub 2020/03/10. doi:
- 450 10.1016/j.ijid.2020.03.003. PubMed PMID: 32147538; PubMed Central PMCID:
- 451 PMCPMC7129213.
- 452 27. Chen J, Xu X, Hu J, Chen Q, Xu F, Liang H, et al. Clinical course and risk factors for
- 453 recurrence of positive SARS-CoV-2 RNA: a retrospective cohort study from Wuhan, China. Aging
- 454 (Albany NY). 2020;12(17):16675-89. Epub 2020/09/11. doi: 10.18632/aging.103795. PubMed
- 455 PMID: 32909961; PubMed Central PMCID: PMCPMC7521537.

456	28. Colson P, Finaud M, Levy N, Lagier JC, Raoult D. Evidence of SARS-CoV-2 re-infection					
457	with a different genotype. J Infect. 2021;82(4):84-123. Epub 2020/11/19. doi:					
458	8 10.1016/j.jinf.2020.11.011. PubMed PMID: 33207255; PubMed Central PMCID:					
459	PMCPMC7666873.					
460	29. Coppola A, Annunziata A, Carannante N, Di Spirito V, Fiorentino G. Late Reactivation of					
461	SARS-CoV-2: A Case Report. Front Med (Lausanne). 2020;7:531. Epub 2020/09/26. doi:					
462	10.3389/fmed.2020.00531. PubMed PMID: 32974374; PubMed Central PMCID:					
463	PMCPMC7468504.					
464	30. de Brito CAA, Lima PMA, de Brito MCM, de Oliveira DB. Second Episode of COVID-19 in					
465	Health Professionals: Report of Two Cases. Int Med Case Rep J. 2020;13(Oct):471-5. Epub					
466	2020/10/17. doi: 10.2147/IMCRJ.S277882. PubMed PMID: 33061670; PubMed Central PMCID:					
467	PMCPMC7537988.					
468	31. Dou C, Xie X, Peng Z, Tang H, Jiang Z, Zhong Z, et al. A case presentation for positive					
469	SARS-CoV-2 RNA recurrence in a patient with a history of type 2 diabetes that had recovered					
470	from severe COVID-19. Diabetes Res Clin Pract. 2020;166:108300. Epub 2020/07/15. doi:					
471	10.1016/j.diabres.2020.108300. PubMed PMID: 32663490; PubMed Central PMCID:					
472	PMCPMC7354258.					
473	32. Du HW, Chen JN, Pan XB, Chen XL, Yixian Z, Fang SF, et al. Prevalence and outcomes of					
474	re-positive nucleic acid tests in discharged COVID-19 patients. Eur J Clin Microbiol Infect Dis.					
475	2021;40(2):413-7. Epub 2020/09/01. doi: 10.1007/s10096-020-04024-1. PubMed PMID:					
476	32865669; PubMed Central PMCID: PMCPMC7456660.					

477 33. Duggan NM, Ludy SM, Shannon BC, Reisner AT, Wilcox SR. Is novel coronavirus 2019

478 reinfection possible? Interpreting dynamic SARS-CoV-2 test results. Am J Emerg Med.

479 2021;39:256 e1- e3. Epub 2020/07/25. doi: 10.1016/j.ajem.2020.06.079. PubMed PMID:

- 480 32703607; PubMed Central PMCID: PMCPMC7335242.
- 481 34. Fu W, Chen Q, Wang T. Letter to the Editor: Three cases of redetectable positive SARS-
- 482 CoV-2 RNA in recovered COVID-19 patients with antibodies. J Med Virol. 2020;92(11):2298-301.
- 483 Epub 2020/05/06. doi: 10.1002/jmv.25968. PubMed PMID: 32369214; PubMed Central PMCID:
- 484 PMCPMC7267393.
- 485 35. Gao G, Zhu Z, Fan L, Ye S, Huang Z, Shi Q, et al. Absent immune response to SARS-CoV-2

in a 3-month recurrence of coronavirus disease 2019 (COVID-19) case. Infection. 2021;49(1):57-

487 61. Epub 2020/07/30. doi: 10.1007/s15010-020-01485-6. PubMed PMID: 32725596; PubMed

488 Central PMCID: PMCPMC7386381.

489 36. Goldman JD, Wang K, Röltgen K, Nielsen SCA, Roach JC, Naccache SN, et al. Reinfection
490 with SARS-CoV-2 and Failure of Humoral Immunity: A case report. medRxiv; 2020.

491 37. Gousseff M, Penot P, Gallay L, Batisse D, Benech N, Bouiller K, et al. Clinical recurrences

492 of COVID-19 symptoms after recovery: Viral relapse, reinfection or inflammatory rebound? J

493 Infect. 2020;81(5):816-46. Epub 2020/07/04. doi: 10.1016/j.jinf.2020.06.073. PubMed PMID:

494 32619697; PubMed Central PMCID: PMCPMC7326402 interest to declare regarding this subject.

- 495 This work had no financial support.
- 496 38. Gupta V, Bhoyar RC, Jain A, Srivastava S, Upadhayay R, Imran M, et al. Asymptomatic
- 497 reinfection in two healthcare workers from India with genetically distinct SARS-CoV-2. Clin

- 498 Infect Dis. 2020. Epub 2020/09/24. doi: 10.1093/cid/ciaa1451. PubMed PMID: 32964927;
- 499 PubMed Central PMCID: PMCPMC7543380.
- 500 39. Habibzadeh P, Sajadi MM, Emami A, Karimi MH, Yadollahie M, Kucheki M, et al. Rate of
- re-positive RT-PCR test among patients recovered from COVID-19. Biochem Med (Zagreb).
- 502 2020;30(3):030401. Epub 2020/08/11. doi: 10.11613/BM.2020.030401. PubMed PMID:
- 503 32774117; PubMed Central PMCID: PMCPMC7394260.
- 40. Hanif M, Haider MA, Ali MJ, Naz S, Sundas F. Reinfection of COVID-19 in Pakistan: A First
- 505 Case Report. Cureus. 2020;12(10):e11176. Epub 2020/12/03. doi: 10.7759/cureus.11176.
- 506 PubMed PMID: 33262913; PubMed Central PMCID: PMCPMC7689968.
- 507 41. Harrington D, Kele B, Pereira S, Couto-Parada X, Riddell A, Forbes S, et al. Confirmed
- 508 Reinfection with SARS-CoV-2 Variant VOC-202012/01. Clin Infect Dis. 2021. Epub 2021/01/10.
- doi: 10.1093/cid/ciab014. PubMed PMID: 33421056; PubMed Central PMCID:
- 510 **PMCPMC7929017**.
- 511 42. He S, Sun W, Zhou K, Hu M, Liu C, Xie L, et al. Clinical Characteristics Analysis of the "Re-

512 positive" Discharged COVID-19 Pneumonia Patients in Wuhan, China. 2020. doi:

- 513 10.21203/rs.3.rs-28667/v1.
- 514 43. Huang J, Zheng L, Li Z, Hao S, Ye F, Chen J, et al. Recurrence of SARS-CoV-2 PCR positivity
- in COVID-19 patients: A single center experience and potential implications. medRxiv; 2020. p.
- 516 2020.05.06.20089573-2020.05.06.
- 517 44. Kapoor R, Nair RK, Nayan N, Bhalla S, Singh J. Reinfection or Reactivation of Coronavirus-
- 518 19 in Patients with Hematologic Malignancies: Case Report Series. SN Compr Clin Med.

- 519 2021;3(2):1-5. Epub 2021/02/16. doi: 10.1007/s42399-021-00790-x. PubMed PMID: 33585797;
- 520 PubMed Central PMCID: PMCPMC7873512.
- 45. Lafaie L, Celarier T, Goethals L, Pozzetto B, Grange S, Ojardias E, et al. Recurrence or
- 522 Relapse of COVID-19 in Older Patients: A Description of Three Cases. J Am Geriatr Soc.
- 523 2020;68(10):2179-83. Epub 2020/07/09. doi: 10.1111/jgs.16728. PubMed PMID: 32638347;
- 524 PubMed Central PMCID: PMCPMC7361461.
- 525 46. Lan L, Xu D, Ye G, Xia C, Wang S, Li Y, et al. Positive RT-PCR Test Results in Patients
- 526 Recovered From COVID-19. JAMA. 2020;323(15):1502-3. Epub 2020/02/28. doi:
- 527 10.1001/jama.2020.2783. PubMed PMID: 32105304; PubMed Central PMCID:
- 528 **PMCPMC7047852**.
- 529 47. Lancman G, Mascarenhas J, Bar-Natan M. Severe COVID-19 virus reactivation following
- treatment for B cell acute lymphoblastic leukemia. J Hematol Oncol. 2020;13(1):131. Epub
- 531 2020/10/04. doi: 10.1186/s13045-020-00968-1. PubMed PMID: 33008453; PubMed Central
- 532 PMCID: PMCPMC7531062.
- 48. Larson D, Brodniak SL, Voegtly LJ, Cer RZ, Glang LA, Malagon FJ, et al. A Case of Early Re-
- 534 infection with SARS-CoV-2. Clin Infect Dis. 2020. Epub 2020/09/20. doi: 10.1093/cid/ciaa1436.
- 535 PubMed PMID: 32949240; PubMed Central PMCID: PMCPMC7543357.
- 49. Li J, Wei X, Tian W, Zou J, Wang Y, Xue W, et al. Clinical features of discharged COVID-19
- 537 patients with an extended SARS-CoV-2 RNA positive signal in respiratory samples. Virus Res.
- 538 2020;286:198047. Epub 2020/06/12. doi: 10.1016/j.virusres.2020.198047. PubMed PMID:
- 539 32522535; PubMed Central PMCID: PMCPMC7833058.

540	50. Li XJ, Zhang ZW, Zong ZY. A case of a readmitted patient who recovered from COVID-19					
541	in Chengdu, China. Crit Care. 2020;24(1):152. Epub 2020/04/18. doi: 10.1186/s13054-020-					
542	02877-8. PubMed PMID: 32299477; PubMed Central PMCID: PMCPMC7160612.					
543	51. Li Y, Hu Y, Yu Y, Zhang X, Li B, Wu J, et al. Positive result of Sars-Cov-2 in faeces and					
544	sputum from discharged patients with COVID-19 in Yiwu, China. J Med Virol. 2020;92(10):1938					
545	47. Epub 2020/04/21. doi: 10.1002/jmv.25905. PubMed PMID: 32311109; PubMed Central					
546	PMCID: PMCPMC7264799.					
547	52. Ling Y, Xu SB, Lin YX, Tian D, Zhu ZQ, Dai FH, et al. Persistence and clearance of viral RN					
548	n 2019 novel coronavirus disease rehabilitation patients. Chin Med J (Engl). 2020;133(9):1039					
549	43. Epub 2020/03/03. doi: 10.1097/CM9.0000000000000774. PubMed PMID: 32118639;					
550	PubMed Central PMCID: PMCPMC7147278.					
551	53. Liu F, Cai ZB, Huang JS, Yu WY, Niu HY, Zhang Y, et al. Positive SARS-CoV-2 RNA recurs					
552	repeatedly in a case recovered from COVID-19: dynamic results from 108 days of follow-up.					
553	Pathog Dis. 2020;78(4):31 Epub 2020/06/28. doi: 10.1093/femspd/ftaa031. PubMed PMID:					
554	32592396; PubMed Central PMCID: PMCPMC7337794.					
555	54. Loconsole D, Passerini F, Palmieri VO, Centrone F, Sallustio A, Pugliese S, et al.					
556	Recurrence of COVID-19 after recovery: a case report from Italy. Infection. 2020;48(6):965-7.					
557	Epub 2020/05/18. doi: 10.1007/s15010-020-01444-1. PubMed PMID: 32415334; PubMed					
558	Central PMCID: PMCPMC7228864.					
559	55. Luo A. Positive SARS-Cov-2 test in a woman with COVID-19 at 22 days after hospital					
560	discharge: A case report. Journal of Traditional Chinese Medical Sciences. 2020;7(4):413-7. doi					
561	10.1016/j.jtcms.2020.04.001.					

562	56.	Mei Q, Li J, Du R, Yuan X, Li M, Li J. Assessment of patients who tested positive for					
563	COVID-19 after recovery. Lancet Infect Dis. 2020;20(9):1004-5. Epub 2020/07/10. doi:						
564	10.1016/S1473-3099(20)30433-3. PubMed PMID: 32645295; PubMed Central PMCID:						
565	PMCPMC7338012.						
566	57. Moore JL, Ganapathiraju PV, Kurtz CP, Wainscoat B. A 63-Year-Old Woman with a						
567	History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was						
568	Serone	gative and Treated with Convalescent Plasma. Am J Case Rep. 2020;21:e927812. Epub					
569	2020/1	10/04. doi: 10.12659/AJCR.927812. PubMed PMID: 33009361; PubMed Central PMCID:					
570	PMCPI	MC7542548.					
571	58.	Mulder M, van der Vegt D, Oude Munnink BB, GeurtsvanKessel CH, van de Bovenkamp J,					
572	Sikkema RS, et al. Reinfection of SARS-CoV-2 in an immunocompromised patient: a case report.						
573	Clin Infect Dis. 2020. Epub 2020/10/13. doi: 10.1093/cid/ciaa1538. PubMed PMID: 33043962;						
574	PubMe	ed Central PMCID: PMCPMC7665355.					
575	59.	Nachmias V, Fusman R, Mann S, Koren G. The first case of documented Covid-19					
576	reinfection in Israel. IDCases. 2020;22:e00970. Epub 2020/10/09. doi:						
577	10.1016/j.idcr.2020.e00970. PubMed PMID: 33029476; PubMed Central PMCID:						
578	PMCPI	MC7528892.					
579	60.	Novoa W, Miller H, Mattar S, Faccini-Martinez AA, Rivero R, Serrano-Coll H. A first					
580	probat	ole case of SARS-CoV-2 reinfection in Colombia. Ann Clin Microbiol Antimicrob.					
581	2021;20(1):7. Epub 2021/01/14. doi: 10.1186/s12941-020-00413-8. PubMed PMID: 33435982;						
582	PubMed Central PMCID: PMCPMC7802059.						

583	61.	Pan L. Wang R	. Yu N. Hu	C. Yan	J. Zhang)	X. et al. Clinio	cal characteristics o	f re-hospitalized
505	<u> </u>		,	e, iaii	, בוומווק /			

- 584 COVID-19 patients with recurrent positive SARS-CoV-2 RNA: a retrospective study. Eur J Clin
- 585 Microbiol Infect Dis. 2021. Epub 2021/01/16. doi: 10.1007/s10096-020-04151-9. PubMed
- 586 PMID: 33447913; PubMed Central PMCID: PMCPMC7808928.
- 587 62. Parry J. Covid-19: Hong Kong scientists report first confirmed case of reinfection. BMJ.
- 588 2020;370:m3340. Epub 2020/08/28. doi: 10.1136/bmj.m3340. PubMed PMID: 32847834.
- 589 63. Patrocinio de Jesus R, Silva R, Aliyeva E, Lopes L, Portugalyan M, Antunes L, et al.
- 590 Reactivation of SARS-CoV-2 after Asymptomatic Infection while on High-Dose Corticosteroids.
- 591 Case Report. SN Compr Clin Med. 2020;2(11):1-4. Epub 2020/10/13. doi: 10.1007/s42399-020-
- 592 00548-x. PubMed PMID: 33043249; PubMed Central PMCID: PMCPMC7531809.
- 593 64. Prado-Vivar B, Becerra-Wong M, Guadalupe JJ, Marquez S, Gutierrez B, Rojas-Silva P, et
- al. A case of SARS-CoV-2 reinfection in Ecuador. Lancet Infect Dis. 2020. Epub 2020/11/27. doi:
- 595 10.1016/S1473-3099(20)30910-5. PubMed PMID: 33242475; PubMed Central PMCID:
- 596 PMCPMC7833993.
- 597 65. Salcin S, Fontem F. Recurrent SARS-CoV-2 infection resulting in acute respiratory distress
- 598 syndrome and development of pulmonary hypertension: A case report. Respir Med Case Rep.
- 599 2021;33:101314. Epub 2020/12/15. doi: 10.1016/j.rmcr.2020.101314. PubMed PMID:
- 600 33312856; PubMed Central PMCID: PMCPMC7718582.
- 601 66. Selhorst P, Van Ierssel S, Michiels J, Marien J, Bartholomeeusen K, Dirinck E, et al.
- 602 Symptomatic SARS-CoV-2 reinfection of a health care worker in a Belgian nosocomial outbreak
- 603 despite primary neutralizing antibody response. Clin Infect Dis. 2020. Epub 2020/12/15. doi:
- 604 10.1093/cid/ciaa1850. PubMed PMID: 33315049; PubMed Central PMCID: PMCPMC7799230.

605	67.	Selvaraj V, Herman K, Dapaah-Afriyie K. Severe, Symptomatic Reinfection in a Patient				
606	with COVID-19. R I Med J (2013). 2020;103(10):24-6. Epub 2020/11/12. PubMed PMID:					
607	33172223.					
608	68. Sharma R, Sardar S, Mohammad Arshad A, Ata F, Zara S, Munir W. A Patient with					
609	Asymptomatic SARS-CoV-2 Infection Who Presented 86 Days Later with COVID-19 Pneumonia					
610	Possib	ly Due to Reinfection with SARS-CoV-2. Am J Case Rep. 2020;21:e927154. Epub				
611	2020/	12/02. doi: 10.12659/AJCR.927154. PubMed PMID: 33257644; PubMed Central PMCID:				
612	РМСР	MC7718490.				
613	69.	Sicsic I, Jr., Chacon AR, Zaw M, Ascher K, Abreu A, Chediak A. A case of SARS-CoV-2				
614	reinfe	ction in a patient with obstructive sleep apnea managed with telemedicine. BMJ Case				
615	Rep.2	021;14(2):240496 Epub 2021/02/03. doi: 10.1136/bcr-2020-240496. PubMed PMID:				
616	33526	540; PubMed Central PMCID: PMCPMC7852971.				
617	70.	Song KH, Kim DM, Lee H, Ham SY, Oh SM, Jeong H, et al. Dynamics of viral load and anti-				
618	SARS-	CoV-2 antibodies in patients with positive RT-PCR results after recovery from COVID-19.				
619	Korea	n J Intern Med. 2021;36(1):11-4. Epub 2020/09/26. doi: 10.3904/kjim.2020.325. PubMed				
620	PMID:	32972123; PubMed Central PMCID: PMCPMC7820639.				
621	71.	Fernandes Valente Takeda C, Moura de Almeida M, Goncalves de Aguiar Gomes R, Cisne				
622	Souza	T, Alves de Lima Mota M, Pamplona de Goes Cavalcanti L, et al. Case Report: Recurrent				
623	Clinica	Il Symptoms of COVID-19 in Healthcare Professionals: A Series of Cases from Brazil. Am J				
624	Trop N	Леd Hyg. 2020;103(5):1993-6. Epub 2020/09/06. doi: 10.4269/ajtmh.20-0893. PubMed				
625	PMID:	32888288; PubMed Central PMCID: PMCPMC7646791.				

626 72. Tian M, Long Y, Hong Y, Zhang X, Zha Y. The treatment and follow-up of 'recurrence'

- 627 with discharged COVID-19 patients: data from Guizhou, China. Environ Microbiol.
- 628 2020;22(8):3588-92. Epub 2020/07/08. doi: 10.1111/1462-2920.15156. PubMed PMID:
- 629 32632947; PubMed Central PMCID: PMCPMC7361525.
- 630 73. To KK, Hung IF, Ip JD, Chu AW, Chan WM, Tam AR, et al. COVID-19 re-infection by a
- 631 phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing.
- 632 Clin Infect Dis. 2020. Epub 2020/08/26. doi: 10.1093/cid/ciaa1275. PubMed PMID: 32840608;
- 633 PubMed Central PMCID: PMCPMC7499500.
- 634 74. Tomassini S, Kotecha D, Bird PW, Folwell A, Biju S, Tang JW. Setting the criteria for SARS-
- 635 CoV-2 reinfection six possible cases. J Infect. 2021;82(2):282-327. Epub 2020/08/18. doi:
- 636 10.1016/j.jinf.2020.08.011. PubMed PMID: 32800801; PubMed Central PMCID:
- 637 PMCPMC7422822.
- 638 75. Torres DA, Ribeiro L, Riello A, Horovitz DDG, Pinto LFR, Croda J. Reinfection of COVID-19
- after 3 months with a distinct and more aggressive clinical presentation: Case report. J Med
- 640 Virol. 2021;93(4):1857-9. Epub 2020/10/29. doi: 10.1002/jmv.26637. PubMed PMID: 33112002.
- 641 76. Van Elslande J, Vermeersch P, Vandervoort K, Wawina-Bokalanga T, Vanmechelen B,
- 642 Wollants E, et al. Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain. Clin
- 643 Infect Dis. 2020. Epub 2020/09/06. doi: 10.1093/cid/ciaa1330. PubMed PMID: 32887979;
- 644 PubMed Central PMCID: PMCPMC7499557.
- 645 77. Vetter P, Cordey S, Schibler M, Vieux L, Despres L, Laubscher F, et al. Clinical, virologic
- and immunologic features of a mild case of SARS-CoV-2 reinfection. Clin Microbiol Infect.

647 2021;2:1-. Epub 2021/02/23. doi: 10.1016/j.cmi.2021.02.010. PubMed PMID: 33618012;

- 648 PubMed Central PMCID: PMCPMC7896115.
- 649 78. West J, Everden S, Nikitas N. A case of COVID-19 reinfection in the UK. Clin Med (Lond).
- 650 2021;21(1):e52-e3. Epub 2020/12/12. doi: 10.7861/clinmed.2020-0912. PubMed PMID:
- 651 33303623; PubMed Central PMCID: PMCPMC7850175.
- 652 79. Wu J, Cheng J, Shi X, Liu J, Huang B, Zhao X, et al. Recurrence of SARS-CoV-2 nucleic acid
- positive test in patients with COVID-19: a report of two cases. BMC Pulm Med. 2020;20(1):308.

654 Epub 2020/11/24. doi: 10.1186/s12890-020-01348-8. PubMed PMID: 33225932; PubMed

- 655 Central PMCID: PMCPMC7681189.
- 656 80. Yadav S, Wadhwa T, Thakkar D, Kapoor R, Rastogi N, Sarma S. Covid19 Reinfection in
- 657 Two Children with Cancer. Authorea Preprints. 2020. doi: 10.22541/au.159986505.57940176.
- 658 81. Yadav SP, Thakkar D, Bhoyar RC, Jain A, Wadhwa T, Imran M, et al. Asymptomatic
- reactivation of SARS-CoV-2 in a child with neuroblastoma characterised by whole genome

660 sequencing. |DCases. 2021;23:e01018. Epub 2020/12/09. doi: 10.1016/j.idcr.2020.e01018.

661 PubMed PMID: 33288996; PubMed Central PMCID: PMCPMC7711173.

662 82. Ye G, Pan Z, Pan Y, Deng Q, Chen L, Li J, et al. Clinical characteristics of severe acute

respiratory syndrome coronavirus 2 reactivation. J Infect. 2020;80(5):e14-e7. Epub 2020/03/17.

doi: 10.1016/j.jinf.2020.03.001. PubMed PMID: 32171867; PubMed Central PMCID:

- 665 **PMCPMC7102560**.
- 666 83. Yoo SY, Lee Y, Lee GH, Kim DH. Reactivation of SARS-CoV-2 after recovery. Pediatr Int.

667 2020;62(7):879-81. Epub 2020/05/19. doi: 10.1111/ped.14312. PubMed PMID: 32421910;

668 PubMed Central PMCID: PMCPMC7276786.

669	84.	Yuan J, Kou S, Liang Y, Zeng J, Pan Y, Liu L. Polymerase Chain Reaction Assays Reverted						
670	to Pos	to Positive in 25 Discharged Patients With COVID-19. Clin Infect Dis. 2020;71(16):2230-2. Epub						
671	2020/04/09. doi: 10.1093/cid/ciaa398. PubMed PMID: 32266381; PubMed Central PMCID:							
672	PMCF	PMC7184423.						
673	85.	85. Zayet S, Royer PY, Toko L, Pierron A, Gendrin V, Klopfenstein T. Recurrence of COVID-19						
674	after recovery ? A case series in health care workers, France. Microbes Infect. 2021:104803.							
675	Epub	2021/03/06. doi: 10.1016/j.micinf.2021.104803. PubMed PMID: 33667643; PubMed						
676	Centr	al PMCID: PMCPMC7923857.						
677	86.	Zhang B, Liu S, Dong Y, Zhang L, Zhong Q, Zou Y, et al. Positive rectal swabs in young						
678	patier	nts recovered from coronavirus disease 2019 (COVID-19). J Infect. 2020;81(2):e49-e52.						
679	Epub	2020/04/27. doi: 10.1016/j.jinf.2020.04.023. PubMed PMID: 32335176; PubMed Central						
680	PMCI	D: PMCPMC7177113.						
681	87.	Zhao W, Wang Y, Tang Y, Zhao W, Fan Y, Liu G, et al. Characteristics of Children With						
682	React	ivation of SARS-CoV-2 Infection After Hospital Discharge. Clin Pediatr (Phila). 2020;59(9-						
683	10):92	29-32. Epub 2020/05/29. doi: 10.1177/0009922820928057. PubMed PMID: 32462940.						
684	88.	Zheng J, Zhou R, Chen F, Tang G, Wu K, Li F, et al. Incidence, clinical course and risk						
685	factor	r for recurrent PCR positivity in discharged COVID-19 patients in Guangzhou, China: A						
686	prosp	ective cohort study. PLoS Negl Trop Dis. 2020;14(8):e0008648. Epub 2020/09/01. doi:						
687	10.13	71/journal.pntd.0008648. PubMed PMID: 32866168; PubMed Central PMCID:						
688	PMCF	PMC7505432.						
689	89.	Zheng KI, Wang XB, Jin XH, Liu WY, Gao F, Chen YP, et al. A Case Series of Recurrent Viral						

690 RNA Positivity in Recovered COVID-19 Chinese Patients. J Gen Intern Med. 2020;35(7):2205-6.

- 691 Epub 2020/04/22. doi: 10.1007/s11606-020-05822-1. PubMed PMID: 32314129; PubMed
- 692 Central PMCID: PMCPMC7169645.
- 693 90. Zhu H, Fu L, Jin Y, Shao J, Zhang S, Zheng N, et al. Clinical features of COVID-19
- 694 convalescent patients with re-positive nucleic acid detection. J Clin Lab Anal.
- 695 2020;34(7):e23392. Epub 2020/06/09. doi: 10.1002/jcla.23392. PubMed PMID: 32506726;
- 696 PubMed Central PMCID: PMCPMC7300578.
- 697 91. Zucman N, Uhel F, Descamps D, Roux D, Ricard JD. Severe reinfection with South African
- 698 SARS-CoV-2 variant 501Y.V2: A case report. Clin Infect Dis. 2021. Epub 2021/02/11. doi:
- 10.1093/cid/ciab129. PubMed PMID: 33566076; PubMed Central PMCID: PMCPMC7929064.
- 700 92. Padda I, Khehra N, Jaferi U, Mosabbeh D, Atwal H, Musaji A, et al. Organ system effects
- and reinfection of COVID-19: A systematic review. Journal of Research in Clinical Medicine.
- 702 2021;9(1):6-. doi: 10.34172/jrcm.2021.006.
- 93. SeyedAlinaghi S, Oliaei S, Kianzad S, Afsahi AM, MohsseniPour M, Barzegary A, et al.
- Reinfection risk of novel coronavirus (COVID-19): A systematic review of current evidence.
- 705 World J Virol. 2020;9(5):79-90. Epub 2020/12/29. doi: 10.5501/wjv.v9.i5.79. PubMed PMID:
- 33363000; PubMed Central PMCID: PMCPMC7747024.
- 707 94. Irfan O, Muttalib F, Tang K, Jiang L, Lassi ZS, Bhutta Z. Clinical characteristics, treatment
- and outcomes of paediatric COVID-19: a systematic review and meta-analysis. Arch Dis Child.
- 709 2021. Epub 2021/02/18. doi: 10.1136/archdischild-2020-321385. PubMed PMID: 33593743.
- 710 95. Gidari A, Nofri M, Saccarelli L, Bastianelli S, Sabbatini S, Bozza S, et al. Is recurrence
- possible in coronavirus disease 2019 (COVID-19)? Case series and systematic review of
- 712 literature. Eur J Clin Microbiol Infect Dis. 2021;40(1):1-12. Epub 2020/10/11. doi:


- 713 10.1007/s10096-020-04057-6. PubMed PMID: 33037944; PubMed Central PMCID:
- 714 PMCPMC7547550.
- 715 96. Vancsa S, Dembrovszky F, Farkas N, Szako L, Teutsch B, Bunduc S, et al. Repeated SARS-
- CoV-2 Positivity: Analysis of 123 Cases. Viruses. 2021;13(3). Epub 2021/04/04. doi:
- 717 10.3390/v13030512. PubMed PMID: 33808867; PubMed Central PMCID: PMCPMC8003803.
- 718 97. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138
- 719 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.
- 720 JAMA. 2020;323(11):1061-9. Epub 2020/02/08. doi: 10.1001/jama.2020.1585. PubMed PMID:
- 32031570; PubMed Central PMCID: PMCPMC7042881.
- 722 98. Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory
- 723 syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis.
- 724 2016;49(Aug):129-33. Epub 2016/06/30. doi: 10.1016/j.ijid.2016.06.015. PubMed PMID:
- 725 27352628; PubMed Central PMCID: PMCPMC7110556.
- 726 99. Wang J, Kaperak C, Sato T, Sakuraba A. COVID-19 reinfection: A Rapid Systematic Review
- of Case Reports and Case Series. medRxiv. 2021:2021.03.22.21254081. doi:
- 728 10.1101/2021.03.22.21254081.
- 100. Choudhary MC, Crain CR, Qiu X, Hanage W, Li JZ. SARS-CoV-2 Sequence Characteristics
- of COVID-19 Persistence and Reinfection. Clin Infect Dis. 2021;(2021). Epub 2021/04/28. doi:
- 731 10.1093/cid/ciab380. PubMed PMID: 33906227.
- 101. Arkhipova-Jenkins I, Helfand M, Armstrong C, Gean E, Anderson J, Paynter RA, et al.
- 733 Antibody Response After SARS-CoV-2 Infection and Implications for Immunity : A Rapid Living

- 734 Review. Ann Intern Med. 2021. Epub 2021/03/16. doi: 10.7326/M20-7547. PubMed PMID:
- 735 33721517; PubMed Central PMCID: PMCPMC8025942.
- 102. Piri SM, Edalatfar M, Shool S, Jalalian MN, Tavakolpour S. A systematic review on the
- recurrence of SARS-CoV-2 virus: frequency, risk factors, and possible explanations. Infect Dis
- 738 (Lond). 2021;53(5):315-24. Epub 2021/01/30. doi: 10.1080/23744235.2020.1871066. PubMed
- 739 PMID: 33508989; PubMed Central PMCID: PMCPMC7852280.
- 103. Azam M, Sulistiana R, Ratnawati M, Fibriana AI, Bahrudin U, Widyaningrum D, et al.
- 741 Recurrent SARS-CoV-2 RNA positivity after COVID-19: a systematic review and meta-analysis.
- 742 Sci Rep. 2020;10(1):20692. Epub 2020/11/28. doi: 10.1038/s41598-020-77739-y. PubMed
- 743 PMID: 33244060; PubMed Central PMCID: PMCPMC7691365.
- 104. Hoang T. Systematic review and meta-analysis of factors associated with re-positive viral
- 745 RNA after recovery from COVID-19. J Med Virol. 2021;93(4):2234-42. Epub 2020/11/03. doi:
- 746 10.1002/jmv.26648. PubMed PMID: 33135788.
- 747 105. NBS. Home Regional Quarterly by Province.
- 748 <u>https://data.stats.gov.cn/english/easyquery.htm?cn=E0102</u>: National Bureau of Statistics, China
- 749 2019.
- 106. Gan N. Beyond India, a growing number of Asian countries are being ravaged by fresh
 coronavirus waves. CNN. 2021 May 8 2021.
- 107. Kothari A, Pfuhl G, Schieferdecker D, Harris CT, Tidwell C, Fitzpatrick KM, et al. The
- 753 Barrier to Vaccination Is Not Vaccine Hesitancy: Patterns of COVID-19 Vaccine Acceptance over
- the Course of the Pandemic in 23 Countries. medRxiv. 2021:2021.04.23.21253857. doi:
- 755 10.1101/2021.04.23.21253857.

- 108. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and
- 757 effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases,
- hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an
- observational study using national surveillance data. The Lancet. doi: 10.1016/S0140-
- 760 6736(21)00947-8.

761 Supporting information

- 762 S1 Table. Search Strategy for MEDLINE
- 763 S2 Table. Characteristics of included studies (N=81)
- 764 S3 Table. Quality assessment of case reports and case series (N=81)
- 765 S1 Fig. Global map of distribution of the studies included (N=81) in the review
- 766 S1 Appendix. PRISMA checklist



	First infection		Reinfection		Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI
Dyspnea	54	577	99	577	12.6%	0.50 [0.35, 0.71]
Fatigue	63	677	87	577	12.8%	0.69 [0.49, 0.98]
Myalgia	80	577	88	577	13.2%	0.89 [0.64, 1.24]
Cough	201	677	201	577	15.0%	1.00 [0.78, 1.27]
Headache	56	577	56	577	11.9%	1.00 [0.68, 1.48]
Sore throat	30	677	29	577	9.3%	1.04 [0.61, 1.75]
Fever	239	577	210	577	15.1%	1.24 [0.97, 1.57]
Diarrhea	45	577	30	577	10.1%	1.54 [0.96, 2.49]
Total (95% CI)		4616		4616	100.0%	0.93 [0.74, 1.17]
Total events	768		800			
Heterogeneity: Tau* =	0.08; Chi ^p	= 25.18	df = 7 (F	e = 0.00	07); * = 7	2%
Test for overall effect	Z=0.61 (8	P = 0.54)			



